DeLLphi-300
DeLLphi-300: Long-term Follow-up From Phase I Study of Tarlatamab, a DLL3-Targeted Bispecific T-Cell Engager, in Previously Treated SCLC

Released: May 13, 2024

Expiration: May 12, 2025

Activity

Progress
1
Course Completed